Precision Cardiology: From Tissue to Therapy, the Translational Model
Precision cardiology is born when tissue biology meets rigorous protocols and reliable data. Targeted biopsies, phenotypic and molecular markers, validation paths and clinical outcomes allow you to transform an intuition into a reproducible therapeutic strategy. Integration with real-world data and algorithms for AI improves diagnostic classification, risk stratification and follow-up, reducing decision-making times and therapeutic uncertainty.
Why start from tissue
Precision in cardiology is not a label, it is a method. Start from direct knowledge of the myocardium, with biopsies performed when indicated and according to defined safety criteria. Reading the sample — histology, immunohistochemistry, ultrastructure, omics profiles when appropriate — returns the actual phenotype of the disease, often different from what imaging alone or the superficial clinical picture may suggest. This step avoids dangerous oversimplifications (“same arrhythmia, same treatment”) and makes it possible to personalise therapy on biological, not just statistical, grounds.
Markers that matter (and how to choose them)
Not all markers have the same weight. The choice depends on the clinical hypothesis and the context. Some describe inflammatory or fibrotic state, others the lysosomal dysfunction or mitochondrial, still others the remodelling. The golden rule is to document specificity, reproducibility and predictive value with respect to the clinical endpoint: if a marker does not change the decision, it is of no use. In a mature translational pathway, marker panels come pre-specified in the protocol and validated on prospective cohorts or observational registries, so as to avoid ex-post reading bias.
Explore the topics
From diagnosis to therapy: the logic of lines
Once the phenotype has been defined, therapy is no longer a “trial-and-error” approach; it becomes a decision pathway through data-driven steps. When mechanisms are clearly identified, the therapeutic rationale becomes stronger: replacement enzymes, pathway modulators, regenerative approaches or devices they are assessed against indicators made measurable by tissue analysis. This reduces the time required to determine whether a strategy is working and when a change of direction is needed. Where appropriate, the pathway is aligned from the outset with EMA/FDA, making subsequent translation into interventional studies or access to rare-disease programmes easier.
Real-world data and AI: from the patient's bedside to useful data
The heart does not live in the laboratory. Telemetry, sensors, extended ECGs, serial imaging, medical records and telemedicine platforms generate a stream of signals that—when properly curated—become reliable real-world data. TheAI enters here: not to replace the clinician, but to recognise patterns that the human eye struggles to identify across long time series, to stratify risk and for predict outcomes when natural history is not linear. Transparent algorithms, trained on clean data and validated with independent protocols, bring the same language of the laboratory into the daily follow-up.
Outcomes that really matter
Precision cardiology is measured by clinical endpoints (mortality, hospitalisations, arrhythmic events, quality of life) and robust surrogates carefully selected (biomarkers, quantitative imaging, arrhythmic burden, functional recovery). Each project should specify a priori the success threshold, observation time and statistical methods, to avoid opportunistic interpretations. The goal is not to demonstrate that an idea is beautiful: it is show that it improves patients' lives and the appropriateness of care pathways.
How to collaborate: what is needed to get started
To rapidly assess a project in the cardiovascular field, we ask for a clear clinical question, the available evidence (including negative findings), theaccess to data and to tissues where applicable, the protocol structure (including ethical criteria), the hypothesis concerning markers and the endpoint. In return, we offer a technical and clinical due diligence, the design of a TRL pathway credible and, where appropriate, support for regulatory affairs and funding (from validation to scalability).
Frequently Asked Questions
The questions you ask us most often
It is an approach that defines the the actual biology of the disease (tissues, markers and omics profiles where indicated) and links it to diagnostic and therapeutic decisions diagnostic and therapeutic personalised. It does not stop at generic classifications or guidelines applied wholesale: it builds a individual pathway measurable through robust clinical endpoints.
An enabling role. The biobanks ensure traceable and comparable samples; the omics broaden the understanding of the underlying mechanisms (inflammatory, metabolic and genetic). When integrated with rigorous protocols and real-world data, make reproducible the evidence and accelerate translation towards clinical trials or clinical adoption.